Literature DB >> 21136310

Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction.

Santiago Garcia1, Timothy D Henry, Yale L Wang, Ivan J Chavez, Wesley R Pedersen, John R Lesser, Gautam R Shroff, Luke Moore, Jay H Traverse.   

Abstract

Reperfusion injury may offset the optimal salvage of myocardium achieved during primary coronary angioplasty. Thus, coronary reperfusion must be combined with cardioprotective adjunctive therapies in order to optimize myocardial salvage and minimize infarct size. Forty-three patients with their first ST-elevation myocardial infarction were randomized to myocardial postconditioning or standard of care at the time of primary coronary angioplasty. Postconditioning was performed immediately upon crossing the lesion with the guide wire and consisted of four cycles of 30 s occlusion followed by 30 s of reperfusion. End-points included infarct size, myocardial perfusion grade (MPG), left-ventricular ejection fraction (LVEF), and long-term clinical events (death and heart failure). Despite similar ischemic times (≅4.5 h) (p = 0.9) a reduction in infarct size was observed among patients treated with the postconditioning protocol. Peak creatine phosphokinase (CPK), as well as its myocardial band (MB) fraction, was significantly lower in the postconditioning group when compared with the control group (CPK--control, 2,444 ± 1,928 IU/L vs. PC, 2,182 ± 1,717 IU/L; CPK-MB--control, 242 ± 40 IU/L vs. PC, 195 ± 33 IU/L; p = 0.64 and p < 0.01, respectively). EF in the postconditioning group was improved when compared with the control group (control, 43% ± 15 vs. PC, 52% ± 9; p = 0.05). After a mean follow-up of 3.4 years, a 6-point absolute difference in LVEF was still evident in the postconditioning group (p = 0.18). MPG was better among patients treated with the postconditioning protocol compared with control (2.5 ± 0.5 vs. 2.1 ± 0.6; p = 0.02). Due to the small sample size no significant differences in clinical events were detected (p value for death = 0.9; p value for heart failure = 0.2). A simple postconditioning protocol applied at the onset of mechanical reperfusion, resulted in reduction of infarct size, better epicardial and myocardial flow, and improvement in left ventricular function. The beneficial effects of postconditioning on cardiac function persist beyond 3 years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21136310     DOI: 10.1007/s12265-010-9252-0

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  37 in total

1.  We think we see a pattern emerging here.

Authors:  James M Downey; Michael V Cohen
Journal:  Circulation       Date:  2005-01-18       Impact factor: 29.690

Review 2.  Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology.

Authors:  Michel Ovize; Gary F Baxter; Fabio Di Lisa; Péter Ferdinandy; David Garcia-Dorado; Derek J Hausenloy; Gerd Heusch; Jakob Vinten-Johansen; Derek M Yellon; Rainer Schulz
Journal:  Cardiovasc Res       Date:  2010-05-06       Impact factor: 10.787

3.  Reperfusion conditions: importance of ensuring gentle versus sudden reperfusion during relief of coronary occlusion.

Authors:  F Okamoto; B S Allen; G D Buckberg; H Bugyi; J Leaf
Journal:  J Thorac Cardiovasc Surg       Date:  1986-09       Impact factor: 5.209

4.  Postconditioning inhibits mitochondrial permeability transition.

Authors:  Laurent Argaud; Odile Gateau-Roesch; Olivier Raisky; Joseph Loufouat; Dominique Robert; Michel Ovize
Journal:  Circulation       Date:  2005-01-10       Impact factor: 29.690

5.  Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways.

Authors:  Xi-Ming Yang; J Bradley Proctor; Lin Cui; Thomas Krieg; James M Downey; Michael V Cohen
Journal:  J Am Coll Cardiol       Date:  2004-09-01       Impact factor: 24.094

6.  Inhibition of myocardial apoptosis by postconditioning is associated with attenuation of oxidative stress-mediated nuclear factor-kappa B translocation and TNF alpha release.

Authors:  Hajime Kin; Ning-Ping Wang; James Mykytenko; James Reeves; Jeremiah Deneve; Rong Jiang; Amanda J Zatta; Robert A Guyton; Jakob Vinten-Johansen; Zhi-Qing Zhao
Journal:  Shock       Date:  2008-06       Impact factor: 3.454

7.  Evaluation of the role of polymorphonuclear leukocytes on contractile function in myocardial reperfusion injury. Evidence for plasma-mediated leukocyte activation.

Authors:  S M Shandelya; P Kuppusamy; M L Weisfeldt; J L Zweier
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

Review 8.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

9.  Time is muscle: translation into practice.

Authors:  Elliott M Antman
Journal:  J Am Coll Cardiol       Date:  2008-10-07       Impact factor: 24.094

10.  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico.

Authors: 
Journal:  Lancet       Date:  1990-07-14       Impact factor: 79.321

View more
  21 in total

1.  Evolving possible link between PI3K and NO pathways in neuroprotective mechanism of ischemic postconditioning in mice.

Authors:  Puja Gulati; Nirmal Singh
Journal:  Mol Cell Biochem       Date:  2014-08-24       Impact factor: 3.396

Review 2.  Ischaemic conditioning: pitfalls on the path to clinical translation.

Authors:  Karin Przyklenk
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

3.  Clinical effect of postconditioning in ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials.

Authors:  Xian-qing Hu; Jian Cheng; Biao Tang; Zhong-heng Zhang; Ke Huang; Yi-ping Yang; Yan-yan Mao; Ming Zhong; Shen-wen Fu
Journal:  J Zhejiang Univ Sci B       Date:  2015-03       Impact factor: 3.066

4.  Controlled pauses at the initiation of sodium nitroprusside-enhanced cardiopulmonary resuscitation facilitate neurological and cardiac recovery after 15 mins of untreated ventricular fibrillation.

Authors:  Demetris Yannopoulos; Nicolas Segal; Scott McKnite; Tom P Aufderheide; Keith G Lurie
Journal:  Crit Care Med       Date:  2012-05       Impact factor: 7.598

Review 5.  Cardioprotection and myocardial reperfusion: pitfalls to clinical application.

Authors:  Richard S Vander Heide; Charles Steenbergen
Journal:  Circ Res       Date:  2013-08-02       Impact factor: 17.367

Review 6.  The therapeutic potential of ischemic conditioning: an update.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  Nat Rev Cardiol       Date:  2011-06-21       Impact factor: 32.419

7.  Ischemic postconditioning at the initiation of cardiopulmonary resuscitation facilitates functional cardiac and cerebral recovery after prolonged untreated ventricular fibrillation.

Authors:  Nicolas Segal; Timothy Matsuura; Emily Caldwell; Mohammad Sarraf; Scott McKnite; Menekhem Zviman; Tom P Aufderheide; Henry R Halperin; Keith G Lurie; Demetris Yannopoulos
Journal:  Resuscitation       Date:  2012-04-18       Impact factor: 5.262

8.  Conditioning the heart to prevent myocardial reperfusion injury during PPCI.

Authors:  Derek J Hausenloy
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-04

Review 9.  Redox signalling and cardioprotection: translatability and mechanism.

Authors:  P Pagliaro; C Penna
Journal:  Br J Pharmacol       Date:  2015-01-12       Impact factor: 8.739

Review 10.  Postconditioning signalling in the heart: mechanisms and translatability.

Authors:  Justin S Bice; Gary F Baxter
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.